

CITATION REPORT

List of articles citing

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

DOI: 10.1111/dom.13082

Diabetes, Obesity and Metabolism, 2018, 20, 378-388.

Source: <https://exaly.com/paper-pdf/69772657/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
69	Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. <i>Current Obesity Reports</i> , 2018 , 7, 147-161	8.4	116
68	Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 343-351	5.4	7
67	Semaglutide: First Global Approval. <i>Drugs</i> , 2018 , 78, 275-284	12.1	32
66	A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2018 , 9, 973-986	3.6	6
65	A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. <i>Advances in Therapy</i> , 2018 , 35, 531-544	4.1	7
64	Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 378-388	6.7	48
63	Semaglutide once-weekly: improved efficacy with a new safety warning. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 1061-1072	3.8	7
62	Semaglutide for the Treatment of Type 2 Diabetes Mellitus. <i>Journal of Pharmacy Technology</i> , 2018 , 34, 281-289	0.6	1
61	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2255-2263	6.7	39
60	Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2018 , 52, 1224-1232	2.9	3
59	Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2018 , 9, 576	5.6	18
58	The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. <i>Endocrine</i> , 2018 , 62, 535-545 ⁴		9
57	Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. <i>Diabetes Therapy</i> , 2018 , 9, 1533-1547	3.6	15
56	Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2019 , 43, 136-145	2.1	26
55	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 188-193	6.7	20
54	The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 2985-2996	4.4	6
53	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. <i>Diabetes Therapy</i> , 2019 , 10, 1645-1717	3.6	17

52	Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment. <i>Diabetes Therapy</i> , 2019 , 10, 735-749	3.6	7
51	Semaglutide as a promising antiobesity drug. <i>Obesity Reviews</i> , 2019 , 20, 805-815	10.6	33
50	Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes and Metabolism</i> , 2019 , 45, 102-109	5.4	10
49	Key milestones in the diabetes research: A comprehensive update. <i>Obesity Medicine</i> , 2020 , 17, 100183	2.6	8
48	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 442-451	6.7	44
47	Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	9
46	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. <i>Cardiovascular Diabetology</i> , 2020 , 19, 156	8.7	10
45	Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist. <i>Clinical Therapeutics</i> , 2020 , 42, 2100-2116	3.5	1
44	Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. <i>Advances in Therapy</i> , 2020 , 37, 4446-4457	4.1	1
43	Response to "Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment". <i>Diabetes Therapy</i> , 2020 , 11, 2443-2446	3.6	
42	Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 392-406	18.1	43
41	Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22 Suppl 4, 24-34	6.7	4
40	Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 377-391	18.1	50
39	The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes. <i>Diabetology International</i> , 2020 , 11, 76-86	2.3	10
38	Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020 , 9, e015323	6	6
37	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 404-414	6.7	14
36	Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment. <i>Advances in Therapy</i> , 2021 , 38, 721-738	4.1	10
35	Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists. <i>Journal of Microencapsulation</i> , 2021 , 38, 249-261	3.4	

34	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. <i>Drugs</i> , 2021 , 81, 1003-1030	12.1	7
33	Safety of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021 , 12, 645563	5.7	7
32	Novel approaches to pharmacological management of type 2 diabetes in Japan. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 2235-2249	4	0
31	Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021 , 12, 695182	5.6	0
30	SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. <i>Annals of Translational Medicine</i> , 2018 , 6, 129	3.2	
29	Clinical potential of treatment with semaglutide in type 2 diabetes patients. <i>Drugs in Context</i> , 2019 , 8, 212585	5.2	2
28	Wegovy (semaglutide): a new weight loss drug for chronic weight management. <i>Journal of Investigative Medicine</i> , 2021 ,	2.9	8
27	[Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines]. <i>Kardiologiya</i> , 2020 , 60, 122-133	1.5	
26	Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022 , 1	10.5	4
25	Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.. <i>Journal of Diabetes Investigation</i> , 2022 ,	3.9	1
24	Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?. <i>Frontiers in Neuroscience</i> , 2022 , 16, 824054	5.1	1
23	The efficacy and safety of once-weekly semaglutide in Japanese subjects with type 2 diabetes by baseline age and body mass index.. <i>Journal of Diabetes Investigation</i> , 2022 ,	3.9	2
22	Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.. <i>JAMA Network Open</i> , 2022 , 5, e221169	10.4	1
21	Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2021 , 42, 17	3.2	1
20	Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	0
19	Image_1.tif. 2018 ,		
18	Image_2.tif. 2018 ,		
17	Image_3.tif. 2018 ,		

16 Table_1.DOCX. 2018,

15 Table_2.DOCX. 2018,

14 Table_3.DOCX. 2018,

13 Table_4.DOCX. 2018,

12 Table_5.DOCX. 2018,

11 Table_6.DOCX. 2018,

10	Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022 , 16, 102511	8.9	o
9	Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. <i>Pharmaceutical Research</i> ,	4.5	o
8	Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes [A systematic review and meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2022 , 108255	3.2	1
7	Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study.		2
6	Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. 2022 , 10, 623-633		4
5	Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. Volume 14, 1463-1476		o
4	Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Volume 16, 4449-4461		o
3	Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.		o
2	GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.		o
1	Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.		o